# Life Science Venture Capital

Life Science Venture Capital is a Venture Capital based in Tokyo, Japan.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Tokyo, Japan
- **Region:** Asia
- **Address:** Tokyo, Japan
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** mblvc.co.jp

## Regulatory record

- **Reports private funds:** No

## About

Life Science Venture Capital is a private equity firm based in Tokyo, Japan. It focuses on venture capital investments. The firm is headquartered in Tokyo.

## Sectors

- Digital Health
- Healthcare Services
- Enterprise Software

## People

- Taro Tanaka — Representative Director & President

## Questions

### Who runs investment decisions at Life Science Venture Capital?

Taro Tanaka serves as Representative Director and President, overseeing all investment decisions. The firm operates as a specialized partnership with Tanaka as the managing principal, reflecting a concentrated decision-making structure common among Japan's boutique venture firms.

### How does Life Science Venture Capital source proprietary deal flow?

The firm leverages deep connections within Japan's university research ecosystem, including relationships with technology licensing offices at institutions such as the University of Tokyo and Osaka University. By targeting the translational gap where academic discoveries struggle to attract generalist venture funding, the firm positions itself as an early gatekeeper for institutional-grade biotech opportunities.

### What investment stages does Life Science Venture Capital typically target?

The mandate spans the full lifecycle from seed-stage proof-of-concept investments to pre-IPO crossover rounds. This allows the firm to support portfolio companies through multiple financing cycles, a structural advantage in Japan where follow-on capital for life-science ventures is often unpredictable.

### Which sectors does Life Science Venture Capital explicitly avoid?

The firm maintains a strict life-science mandate and does not invest in general information technology, consumer internet, or industrial sectors. Within healthcare, its known posture avoids pure-play service businesses without a technology or IP component, focusing instead on drug discovery platforms, medical devices, and digital health infrastructure.

## Related profiles

- [Liberty Partners](https://altss.com/profile/liberty-partners)
- [Life.SREDA](https://altss.com/profile/lifesreda)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/life-science-venture-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology